Shares were up 13%—erasing losses in the year to date—after the company raised its annual guidance for the second time this year, citing strong U.S. demand for its blockbuster drug.
Source link
About The Author
UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook